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METHODS:
We used a simulation model made of 2 decision analytic sub-models. The first sub-model (second order Montecarlo simulations) generated patient's cohort and simulated lipid changes after treatment. Baseline cohort characteristics were taken from a Pan-European Survey on HDL-c prevalence (Swedish diabetic sub-group). Niaspan ® treatment effects were taken from the ARBITER II study. Patients with low HDL-c (<1.03 mmol/L) on statin treatment received either add-on Niaspan ® (1 g/day) or continued statin alone. The second submodel (Markov) calculated the risk of coronary heart disease events based on Framingham risk formulae. Direct medical costs (SEK) were accounted from a third-party payer perspective. Annual discount rates of 3% were applied to costs and clinical benefits. Simulations were run to capture patient lifetimes. RESULTS: Niaspan ® + statin was associated with an increase in discounted life expectancy (0.20 years) compared to statin alone. Direct medical costs were on average SEK34,320 higher in the Niaspan ® + statin group leading to an Incremental Cost-Effectiveness Ratio of SEK169,696 per Life Year Gained (ICER < SEK190,000/LYG is highly cost-effective). CONCLUSION: In the Swedish setting, raising HDL-c with the addition of Niaspan ® to statin treatment increases life expectancy and is highly costeffective compared to statin monotherapy in T2D patients with dyslipidemia and persistently low HDL-c.
